Zhi Tong Cai Jing·2026-02-27 11:34Core Viewpoint - Rongchang Biopharma (09995) reported a significant increase in revenue and profitability for the fiscal year 2025, indicating strong business performance driven by product sales and licensing agreements [1] Financial Performance - The company achieved total revenue of RMB 3.251 billion, representing a year-on-year increase of 89.36% [1] - Net profit attributable to the parent company was RMB 709 million, marking a turnaround from a loss to profitability [1] - Basic earnings per share were RMB 1.29 [1] Revenue Drivers - The increase in revenue was primarily due to higher sales volumes of injectable Tisotumab Vedotin and injectable Vedolizumab, contributing to increased sales revenue [1] - Additionally, the company granted Vor Biopharma Inc. exclusive global development and commercialization rights for Tisotumab Vedotin outside Greater China, leading to a substantial increase in licensing revenue [1]